|
Title
|
Publication Date
|
Price
|
Relevance
|
The Future of Nutrigenomics
New Opportunities in Personalized Nutrition and Food-Pharma Collaboration
|
Jan 2010 |
£3,030 |
100% |
Orphan Drugs to 2008
Understanding regulation & market opportunity in Europe
|
Jan 2005 |
£995 |
99% |
|
Opportunities in Orphan Drugs: Strategies for developing maximum returns from niche indications
|
Jan 2010 |
£2,425 |
99% |
Orphan Drug Markets in Europe
Key developments and the strategies of major pharmaceutical companies
|
Nov 2011 |
£1,495 |
98% |
Endpoints-Clinical Trials in Orphan Diseases
Highest Number of Terminated Trials Focused on Mulitiple Myeloma
|
Jan 2012 |
£2,215 |
93% |
The Future of Orphan Diseases Therapeutics
Market Forecasts to 2015
|
Dec 2009 |
£2,215 |
92% |
Orphan Australia Pty Ltd - Product Pipeline Review
Q4 2010
|
Nov 2010 |
£315 |
92% |
FDA Office of Orphan Products Development – Developmental Therapeutics Review
Q4 2010
|
Nov 2010 |
£315 |
90% |
|
Pricing and Reimbursement Risk and Opportunity in Pharmaceutical Deal Making
|
May 2007 |
£1,695 |
86% |
Jazz Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
85% |
Alexion Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
83% |
4SC AG – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
82% |
Sweden Pharmaceuticals and Healthcare Report Q2
2011
|
Feb 2011 |
£330 |
81% |
Recordati S.p.A. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
81% |
Drug Approval Trends at the FDA and EMEA
Process Improvements, Heightened Scrutiny and Industry Response
|
Apr 2008 |
£2,425 |
81% |
AmpliMed Corporation – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
80% |
|
Angiongenesis Inhibitors and Stimulators
|
Feb 2011 |
£3,130 |
80% |
BioAlliance Pharma SA – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
79% |
QLT Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
79% |
ZIOPHARM Oncology, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
79% |
|
Global Market: Biopharmaceuticals Market Trends & Competition
|
Jun 2010 |
£1,450 |
77% |
|
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006
|
Mar 2006 |
£1,265 |
76% |
ERYtech Pharma – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
76% |
|
Companion Biomarkers in Drug Development
|
Apr 2009 |
£2,150 |
74% |
Biogen Idec Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
74% |
CytRx Corporation – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
74% |
Stakeholder Opinions: Spinal Cord Injury
Attractive niche market with multi-billion dollar potential
|
Mar 2010 |
£2,405 |
74% |
Emergent BioSolutions Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
73% |
Wilex AG – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
73% |
Pharmaceutical Product Approval Trends, 2007
Key Market Benchmarks And Strategic Insights
|
Dec 2007 |
£1,299 |
73% |
